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TITLE OF CASE  
Anti-LGI1-encephalitis causing faciobrachial dystonic seizures 
 
 
SUMMARY  
 
Anti-LGI1-encephalitis has an autoimmune origin and can be reversed with 
immunotherapy.  
It is obvious that identifying and treating this condition early is of paramount 
importance. We present the case of a 69-year-old man who was admitted to hospital 
with faciobrachial dystonic seizures and was found to have antibodies to leucine-rich 
glioma inactivated protein 1 (LGI1). His symptoms started approximately 3 months prior 
admission to the hospital. There had also been some subtle cognitive impairment. He 
was treated with two courses of intravenous immunoglobulin and commenced on 
prednisolone 50 milligrams daily and clonazepam 500 micrograms at night. Despite 
these treatments, his seizures were becoming progressively more frequent and severe. 
He then underwent treatment with a course of plasma exchange followed by an 
intravenous infusion of methylprednisolone and returned to his previous baseline 
function. 
 
 
 
BACKGROUND Why you think this case is important – why did you write it up? 
 
Voltage-gated potassium channel (VGKC) antibodies were detected in 1995, in patients 
suffering from neuromyotonia.[1]  
The clinical presentation of this pathology ranged significantly and several different 
descriptions were given.That raised the question how such a wide range could be 
attriuted to one antibody.  
Indeed, in 2010 the identification of two proteins, the leucine-rich, glioma inactivated 1 
protein (LGI1) and the contactin-associated protein-2 (Caspr2), as a target of the 
antibodies enabled us to understand better this autoimmune disorder.[2][3] 
 
Anti-LGI1-encephalitis is an antibody-associated inflammation of the limbic system of the 
brain. It is a rare disease.The annual incidence of this disease is the Netherlands is 0.83 
per million. There have been around 300 patients, so far, reported. The clinical 
presentation involves a subacute onset of frequent short seizures with patients exhibiting 
disturbances in memory and behaviour. There is an association with tumours in 5 to 
10% of the cases with the most common being thymomas.[4] 
 
Contactin-associated protein-like 2 (Caspr2) is a membrane protein expressed in the 
central nervous system (CNS) and peripheral nervous system (PNS). There is more 
diversity in regards to the clinical presentation of Caspr2 antibodies related disease. The 
majority of the cases with antibodies to Caspr2 present with Morvan syndrome, epilepsy, 
or pain syndromes. There have been reports with positive Caspr2 antibodies in patients 
with antibodies to LGI1. The clinical presentation of Caspr2 remains not well defined.[5] 
 
There is an association between Caspr2 and other proteins in the PNS and in CNS and 
more specifically the transiently-expressed axonal glycoprotein (TAG1), the post synaptic 
density Protein-Drosophila disc large tumour suppressor-zonula occludens-1 protein 
(PDZ), and the ankyrin-spectrin protein. 
  
According to a large clinicoserologic study it has been observed that LGI1 and Caspr2 
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autoantibodies are associated with diverse neurologic phenotypes that often overlap. The 
commonest presentation is limbic encephalitis(LE) in the CNS and neuromyotonia or 
Morvan’s syndrome in the PNS.[6] 
 
This case highlights characteristic features such as seizures and hyponatremia that are 
typical of Anti-LGI1-encephalitis. The case report illustrates the importance of antibody 
testing and imaging in classification and identifying this condition, which is often 
undiagnosed.  
 
The use of the term Anti-LGI1-encephalitis is proposed and this disorder should be 
classed as an autoimmune synaptic encephalopathy. 
 
 
 
CASE PRESENTATION Presenting features, medical/social/family history 
 
A 69-year-old man complained of vague, non-specific symptoms and of “generally not 
right” for six months. He complained of lethargy, a protracted period of soreness in the 
throat between March and June 2013 and then a 3-month history of abnormal 
movements described as spasms affecting his left face, arm and leg and occasionally, 
affecting the right side. The spasms lasted only for a second and he appeared to retain 
awareness but his speech was transiently disturbed and he lost his train of thought 
briefly. The spasms occurred every few minutes throughout the day but generally 
remitted in sleep, although his wife had witnessed this during his sleep. 
  
The patient was a retired professor of veterinary medicine and felt that his cognition had 
been slightly impaired in recent months. He also reported an episode for one month 
where he had extremely cold extremities. There was a travel history of visiting Brazil 
including the rain forest areas in January 2013. Apart from a severe migraine with an 
episode of expressive dysphasia during that visit, which he attributed to jetlag, he was 
otherwise well. He had also visited Eastern Europe and India within the last 12 months. 
In India, he experienced severe gastroenteritis. There was no history of fever, rash, 
cough, hallucination, delusions or bleeding. However, he had lost 4 kilograms of body 
weight and had been more somnolent than usual by day and insomniac at night. He 
injured his left elbow in September prior admission to hospital and subsequently 
developed swelling, redness and tenderness at the site.   
 
Examination showed that his cognition was slightly reduced with Addenbrooke's 
Cognitive Examination-Revised test (ACE-R): 93/100 and Mini–Mental State Examination 
(MMSE): 29/30 but this was not evident during general conversation.[7] His movement 
disorder was observed by Neurology team, in line with the description given above. It 
was thought that the diagnosis may have been consistent with a faciobrachial dystonic 
seizure. Cranial nerve examination was normal. In the limbs, power, tone, reflexes, 
sensation and co-ordination was normal. Fasciculations were observed in both 
gastrocnemius muscles. The left elbow showed features consistent with an olecranon 
bursitis, which was initially hot, erythematous and slightly indurated.   
 
INVESTIGATIONS If relevant 
 
Blood investigations revealed hyponatraemia with features in keeping with the syndrome 
of inappropriate antidiuretic hormone secretion (SIADH): Na 126 mmol/L, urine 
osmolality 764 mmol/kg H2O, Urine sodium 106 mmol/L and serum osmolality 267 
mOsm/kg H2O. A full blood count showed only mild lymphopaenia (1.1 ×109/L) but 
indices were otherwise normal. The calcium, phosphate, magnesium, liver function tests, 
c-reactive protein (CRP), creatine kinase (CK), glucose, thyroid function, ferritin, human 
immunodeficiency virus (HIV) serology, immunoglobulins and serum electrophoresis, 
serum angiotensin converting enzyme (ACE) and antistreptococcal antibody titres 
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(ASOT) were all normal or negative. Autoantibodies that were negative included anti 
nuclear (ANA), against double stranded DNA (anti ds-DNA), antineutrophil cytoplasmic 
(ANCA), extractable nuclear antigens screen tests (ENA) for: Anti-Sm antibodies (anti-
Sm)/ small nuclear ribonucleoprotein (anti-RNP) antibodies / antibodies to the La antigen 
(anti-La)/ antibodies to the Ro antigen (anti-Ro)/ anti-topoisomerase I antibodies (anti-
Scl70)/ antibodies to the cytoplasmic protein (anti-Jo-1).  
 
Basal ganglia and neuronal antibodies (anti Yo, anti Hu, anti Ri) were negative as well. 
Antibodies against the voltage gated potassium channel (anti-VGKC) were strongly 
positive (1002 pM, normal <100) and antibodies to leucine-rich glioma inactivated 
protein 1 (LGI1) were positive as well. Antibodies against contactin-associated protein 
(anti-CASPR), anti-N-methyl-d-aspartate receptor (anti-NMDA), antiglutamic acid 
decarboxylase (anti GAD), anti-Amphiphysin antibodies and Glycine receptor antibodies 
were negative. Serum Caeruloplasmin and copper levels were normal. 
 
Cerebrospinal fluid (CSF) examination showed acellular fluid, no bacterial growth, normal 
biochemistry and no evidence of oligoclonal bands. The opening pressure was normal. 
CSF cytology showed a hypocellular deposit with scanty small lymphocytes and 
histiocytes but no malignant cells.  
 
Hepatitis B virus surface antigen (HBV), Hepatitis C virus IgG assay, Hepatitis B surface 
antibody (anti-HBs) tests were all negative or normal. Serology for American 
Trypanosomiasis was negative. Joint aspirations from the left olecranon bursa on two 
ocassions, both revealed Klebsiella oxytoca after extended incubation.  
 
A CT scan of the thorax showed calcified nodules in both upper lung lobes measuring 3-4 
mm inside, which were reported as being benign. However, there were several other 
non-calcified pulmonary nodules, the largest of which was in the right lower lobe, 
measuring 7 mm. There was no hilar or mediastinal lymphadenopathy. Abdominal and 
pelvic organs were normal.   
 
The patient had two electroencephalograms and was not felt to show any epileptiform 
discharges.  
 
A Consultant Neuroradiologist reviewed the MRI brain scans. 
T2-Flair showed an ill-defined hyperintense signal, involving the left side of the medial 
temporal lobe (figure 1). There was no significant mass effect and no haemorrhagic 
changes in the coronal views (figure 2). The axial flair showed mild assymetrical 
enlargement and faint increased signal intensity in the left side of the medial temporal 
lobe/hippocampus (figure 3). 
 
 
Nerve conduction studies showed small upper and lower limb sensory potentials but 
normal motor studies except for a mild reduction in lower limb motor conduction 
velocity. Electromyogram (EMG) was normal, in particular, showing no evidence of 
neuromyotonia. 
 
Echocardiogram showed dilated right heart but good left ventricular and right ventricular 
systolic function. There was leaflet mitral valve prolapse with mild to moderate mitral 
regurgitation and the left atrium was mildly enlarged.  
 
DIFFERENTIAL DIAGNOSIS If relevant 
 
It is extremely important to make the right diagnosis as early as possible and it is 
necessary to exclude the presence of underlying malignancy, as it can be associated with 
this pathology.[8] In this case there was nothing to suggest the presence of neoplasia.  
At the initial stage the differential diagnosis included: 
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Hashimoto's encephalopathy— there was no evidence of thyroiditis and thyroid function 
tests were normal. 
Hepatic encephalopathy—the liver function tests were normal and radiological findings 
were unremarkable with no evidence of ascites. 
Wernicke-Korsakoff's encephalopathy—patient had minimal alcohol consumption. 
Infectious encephalopathy—several forms of infections that could lead to encephalopathy 
were excluded. 
Neurosarcoidosis: the imaging and laboratory tests were not supportive of the diagnosis, 
ACE levels were normal. 
Wilson's disease— serum caeruloplasmin and copper levels were normal. 
Hypertensive encephalopathy—the blood pressure readings were normal throughout the 
admissions. 
Uremic encephalopathy—the kidney function was normal. 
Ischaemic encephalopathy related to hypoxia—there were no changes on the MRI head 
scan suggestive of this diagnosis. 
 
TREATMENT If relevant  
 
Despite the patient being commenced on high dose oral Prednisolone at a dose of 50 mg 
daily and having had two five day courses of intravenous immunoglobulin (IVIg) at a 
dose of 0.4 g/kg/day for 5 days, there was no satisfactory clinical response. 
He was commenced on Clonazepam 0.5 mg at night for the seizures. Whilst being on the 
ward his hyponatraemia required ongoing monitoring without fluid restriction.   
An oral course of oral amoxicillin/clavulanic acid at a dose of 625 mg three times daily 
for seven days was given for left infected olecranon bursitis.  Once the extended culture 
results were back, that showed growth of Klebsiella oxytoca and anaerobes, he had a 
course of oral Ciprofloxacin 500 mg twice daily for two weeks, given that he was being 
commenced on immunomodulatory therapy and had mild ongoing symptoms of bursitis. 
Whilst being on treatment with steroids he had to be admitted to a district general 
hospital, as needed urgent surgery for a perforated duodenal ulcer, likely secondary to 
steroids. When transferred back under the Neurology team the case was discussed with 
surgical team that felt it was safe to restart oral steroids with proton pump inhibitor 
prophylaxis so he was put back on oral Prednisolone 50 mg daily and Omeprazole 20 mg 
twice daily.The patient was discharged and advised to continue steroids for the long term 
at the same dose until seen by the Consultant Neurologist at outpatients clinic after 
seven days .At that point the cognition appeared to have improved with an ACE-R score 
of 96/100(previously 93).The possibility of an additional course of IVIg was mentioned to 
the patient for the near future. 
After getting expert advice on his management from the Nuffield Department of Clinical 
Neurosciences, University of Oxford, he finally underwent a course of plasma exchange 
(PLEX) for five days. After a week this was followed by a three-day course of intravenous 
infusion of methylprednisolone at a dose of 1 gram daily for three days with very good 
effect. (figure 4).  
The patient was discharged on oral Prednisolone 50mg that was tapered over six months 
Interestingly, the fact that the patient suffered from infections and had surgery must 
have deteriorated his autoimmune disorder. 
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OUTCOME AND FOLLOW-UP  
 
The patient has had regular follow-up appointments with the Neurology team on an 
outpatient basis for three years .He was finally discharged back into the community. 
There has been no relapse of his anti-LGI1 encephalitis. 
 
DISCUSSION Include a very brief review of similar published cases  
 
The clinical presentation of autoimmune encephalitis cases is broad. There are patients 
that have antibodies against LGI1, against Caspr2 and finally patients who do not have 
any of these but still are VGKC positive. 
 
This classification might enable the clinicians to perform a more accurate diagnosis and 
at an earlier stage which is crucial for the patient. The reason being that these antibodies 
cause different syndromic pictures and more specifically the patients with LGI1-
antibodies present with limbic encephalitis, hyponatremia and typical faciobrachial 
dystonic seizures like in our case. Caspr2-antibodies rarely cause hyponatremia, affect 
older male patients with peripheral or central nervous system symptoms. Morvan’s 
syndrome is associated with Caspr2-antibodies. Both of these two different entities 
might benefit from immunotherapy.[9] 
 
The class that lacks the aforementioned antibodies affects all ages with no sex 
difference. The presentation includes pshychiatric symptomatology, epilepsy, cognitive 
decline and cramp fasciculation syndromes. 
 
The patient within this case report had characteristics of anti-LGI1-encephalitis as he  
was 69 years old, had faciobrachial dystonic seizures (FBDS), hyponatremia and 
evidence of mild cognitive decline. His seizures improved instantly with the plasma 
exchange another factor suggesting anti-LGI1-encephalitis. It is more than evident that 
nowadays there is a new subgroup of clinical syndromes with patients having positive 
antibodies against LGI1 and Caspr2. It is therefore necessary for the clinician to further 
distinguish these cases with the help of the relevant investigations and the associated 
characteristic clinical picture. Our case demonstrates positively how important is to keep 
in mind this categorization in order to reach to the right diagnosis at an early stage and 
give the most appropriate treatment. 
 
A recent study which assessed the clinical relevance of a positive voltage-gated 
potassium channel (VGKC) test in patients lacking antibodies to LGI1 and Caspr2 showed 
that VGKC positivity is not a clear marker for autoimmune inflammation and not clinically 
relevant.[10][11] 
 
In the last few years, a variety of new antibodies targeting cell-surface proteins 
associated with distinct clinical syndromes have been discovered. Despite the wide range 
of different antibody targets, many of these syndromes present with features of limbic 
encephalitis and corresponding T2/FLAIR hyperintense signal alterations in the medial 
temporal lobes including the hippocampus. This includes patients with antibodies 
directed against LGI1.[12] 
 
In conclusion, this case illustrates the need to be more specific when referring to this 
disease, as there is a broad spectrum of clinical presentation. In the future, when trying 
to describe these cases, as they are completely different clinical entities, we have to use 
a distinct term. 
This change in the terminology will enable the better understanding and management of 
these syndromes, which possibly are more common than we think. 
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LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a 
required field 
 
• A new classification for VGKC-positive patients should be used: LGI1 & Caspr2 positive 
or negative.   
• Anti-LGI1-encephalitis cases present with limbic encephalitis, hyponatremia and 
typical faciobrachial dystonic seizures. 
• Caspr2-antibody mediated disease affects predominantly older male patients with 
central nervous system manifestations like limbic encephalitis, peripheral nervous 
hyperexcitability or a  combination of both such as Morvan’s syndrome.   
• Immunotherapy is beneficial for both anti-LGI1 and anti-Caspr2 disease. Underlying 
tumour has to be excluded. 
• Anti-LGI1-encephalitis presents with T2-Flair hyperintense signal alterations in the 
medial temporal lobes including the hippocampus that may progress to atrophy. 
In many cases, basal ganglia are affected as well. .  
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• FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this 
document 
Figure 1 : MRI brain scan T2-Flair showing an ill-defined hyperintense signal, involving the 
left side of the medial temporal lobe. 
Figure 2 : MRI brain scan coronal view showing no significant mass effect and no 
haemorrhagic changes. 
Figure 3 : MRI brain axial flair showing mild assymetrical enlargement and faint increased 
signal intensity in the left side of the medial temporal lobe/hippocampus  . 
Figure 4 : Spasms of the patient per 24 hours 
 
 
 
 
 
 
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
“From my perspective plasmapheresis seemed to be spectacularly effective at controlling the 
spasms. The side effects of the corticosteroids were so wide ranging and life changing that I 
wonder if alternatives to this aspect of treatment should be researched? Perhaps they are?” 
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